Cell-Free DNA (cfDNA) Blood Collection Tube Market Report 2026

Cell-Free DNA (cfDNA) Blood Collection Tube Market Overview

• Cell-Free DNA (cfDNA) Blood Collection Tube market size has reached to $1.33 billion in 2025 • Expected to grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 13.3% • Growth Driver: Surge In Respiratory Disorder Cases Fueling The Growth Of The Market Due To Rising Air Pollution And Hospitalizations • Market Trend: Labcorp’s Acquisition Of Personal Genome Diagnostics Enhances cfDNA-Based Cancer Diagnostics And Precision Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell-Free DNA (cfDNA) Blood Collection Tube Market?

A cell-free DNA (cfDNA) blood collection tube is a specialized device used to collect, stabilize, and transport blood samples for cfDNA analysis. It is formulated with preservatives that protect nucleic acids from degradation and limit the release of genomic DNA from white blood cells. These tubes ensure accurate and reliable results in downstream applications such as liquid biopsy, prenatal testing, and cancer diagnostics. The main types in the cell-free DNA (cfDNA) blood collection tube market are 5 mL and 10 mL. The 5 mL cell-free DNA (cfDNA) blood collection tube refers to a smaller-volume blood collection tube used for individual or routine sample collection. The various sample types include plasma, serum, and whole blood. The different applications encompass in vitro diagnostics and scientific research. The key end-users include diagnostic laboratories, hospitals or clinical centers, genetic diagnostic labs, cancer research centers, research and development institutions, and conventional diagnostic centers.

What Is The Cell-Free DNA (cfDNA) Blood Collection Tube Market Growth Forecast?

The cell-free dna (cfdna) blood collection tube market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to innovation in blood tube preservatives, integration with AI diagnostics, growing liquid biopsy market, expansion of clinical trials, rising demand in emerging markets. Major trends in the forecast period include enhanced sample preservation, integration with liquid biopsy platforms, standardized blood collection protocols, automation in sample processing, high-stability tube designs.

Global Cell-Free DNA (cfDNA) Blood Collection Tube Market Segmentation

1) By Type: 5ml, 10ml 2) By Sample Type: Plasma, Serum, Whole Blood 3) By Application: In Vitro Diagnostics, Scientific Research 4) By End-User: Diagnostic Laboratories, Hospitals Or Clinical Centers, Genetic Diagnostic Labs, Cancer Research Centers, Research And Development Institutions, Conventional Diagnostic Centers Subsegments: 1) By 5 mL: Single Use Tube, Vacuum Blood Collection Tube, Gel Separator Tube 2) By 10 mL: Double Draw Tube, High Volume Collection Tube, Anticoagulant Treated Tube

What Are The Drivers Of The Cell-Free DNA (cfDNA) Blood Collection Tube Market?

The increasing prevalence of respiratory disorders is expected to drive the growth of the cell-free DNA (cfDNA) blood collection tube market in the future. Respiratory disorders are medical conditions that affect the lungs and other parts of the respiratory system, impairing the ability to breathe efficiently and deliver oxygen to the blood or remove carbon dioxide from the body. The increasing prevalence of respiratory disorders is largely due to air pollution, which irritates the airways, reduces lung function, and increases the risk of conditions like asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Cell-free DNA (cfDNA) blood collection tubes are used in the management of respiratory disorders to detect genetic mutations, monitor disease progression, and assess treatment response through a simple blood test, thereby reducing the need for invasive lung biopsies. For instance, in December 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, between October 1 and November 30, 2024, an estimated 17,000 to 34,000 hospitalizations were caused by respiratory syncytial virus (RSV). Therefore, the increasing prevalence of respiratory disorders is driving the growth of the cell-free DNA (cfDNA) blood collection tube industry. The increasing incidence of cancer is expected to drive the growth in the cell-free DNA (cfDNA) blood collection tube market going forward. The incidence of cancer is increasing due to lifestyle factors such as poor diet, smoking, and lack of exercise. Cell-free DNA (cfDNA) blood collection tubes are used in cancer management to perform liquid biopsies, allowing detection of tumor-related genetic mutations, monitoring of disease progression, assessment of treatment response, and identification of resistance mutations through a simple blood test, reducing the need for invasive tissue biopsies. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, the number of cancer survivors in the United States is expected to reach 26 million by 2040 from 18.1 million in 2022. Therefore, the increasing incidence of cancer drives the growth of the cell-free DNA (cfDNA) blood collection tube industry.

Key Players In The Global Cell-Free DNA (cfDNA) Blood Collection Tube Market

Major companies operating in the cell-free dna (cfdna) blood collection tube market are Roche Holding AG, Thermo Fisher Scientific Inc., Becton Dickinson (BD), Qiagen N.V., SARSTEDT AG & Co. KG, Guangzhou Improve Medical Technology, Streck Inc., DiaCarta Inc., Zymo Research Corporation, Biomatrica Inc., PreAnalytiX GmbH, Beijing Cowin Bioscience Co.Ltd., Norgen Biotek Corporation, Nonacus Limited, Guangdong Ardent Biomed Co. Ltd, MagBio Genomics Inc., VanGenes, BEAVER, Hebei Xinle Science & Technology Co. Ltd., Nasmed Diagnostics Pvt. Ltd.

Global Cell-Free DNA (cfDNA) Blood Collection Tube Market Trends and Insights

Major companies operating in the cell-free DNA (cfDNA) blood collection tube market are focusing on automation of cfDNA extraction to enhance workflow efficiency. Automation of cfDNA extraction refers to the use of advanced robotic instruments and standardized protocols to isolate cell-free DNA from blood samples with minimal manual intervention, improving efficiency, accuracy, and consistency while reducing turnaround time and human error. For instance, in September 2023, Yourgene Health plc, a UK-based molecular diagnostics company, launched the MagBench Automated DNA Extraction Instrument and Kit, offering a fast, simple, and cost-efficient bench-top robotic solution optimized for cell-free DNA extraction in non-invasive prenatal testing (NIPT) workflows. This launch aims to strengthen automation in NIPT workflows by delivering higher throughput, reproducibility, and reliability in cfDNA extraction while reducing hands-on time and operational costs.

Regional Outlook

North America was the largest region in the cell-free DNA (cfDNA) blood collection tube market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cell-Free DNA (cfDNA) Blood Collection Tube Market?

The cell-free DNA (cfDNA) blood collection tube market consists of sales of plasma separation tubes, cryogenic storage systems, and plasma prep centrifugation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.